AstraZeneca
Compare AstraZeneca…UK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AstraZenecaUK-Swedish diversified pharma. AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1) build a credible third-tier obesity franchise behind Lilly and Novo.
AZD6234 (oral amylin agonist, APRICUS Phase 2b completing 2026) and ECC5004 (oral GLP-1). Building a credible third-tier biopharma franchise behind Lilly and Novo.